{"entity":{"id":"alice-shaw","kind":"person","name":"Alice T. Shaw","aka":[],"tldr":"Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs.","summary":"Alice Shaw led the clinical development of ALK and ROS1 inhibitors while at Massachusetts General Hospital. She was first author of the 2014 New England Journal of Medicine report showing crizotinib's activity in ROS1-rearranged non-small-cell lung cancer, which led to its approval for that indication, and led trials of ceritinib, alectinib and lorlatinib and studies of ALK resistance mutations. In 2019 she moved to Novartis to lead translational clinical oncology.","asOf":"2026-09-18","links":[],"tags":["lung","targeted-therapy","trialist"],"related":[],"cancers":["ros1-positive-nsclc","nsclc","lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-shaw-crizotinib-ros1-nejm-2014"],"journals":[],"dependsOn":[],"notes":[],"role":"Thoracic oncologist and drug developer","specialisms":["ALK-positive lung cancer","ROS1-positive lung cancer","Kinase inhibitor resistance"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shaw%5BAuthor%5D"}],"papers":[{"title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","journal":"New England Journal of Medicine","year":2014,"url":"https://doi.org/10.1056/NEJMoa1406766","doi":"10.1056/NEJMoa1406766"}]},"route":"/people/alice-shaw/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"paper":[{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/"},{"id":"paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019","kind":"paper","name":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","route":"/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/"},{"id":"paper-kwak-crizotinib-alk-nsclc-nejm-2010","kind":"paper","name":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","route":"/key-papers/paper-kwak-crizotinib-alk-nsclc-nejm-2010/"},{"id":"paper-shaw-crizotinib-ros1-nejm-2014","kind":"paper","name":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","route":"/key-papers/paper-shaw-crizotinib-ros1-nejm-2014/"},{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/"},{"id":"paper-shaw-alk-l1198f-resensitisation-nejm-2016","kind":"paper","name":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","route":"/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/"},{"id":"paper-bergethon-ros1-rearrangements-lung-jco-2012","kind":"paper","name":"ROS1 rearrangements define a unique molecular class of lung cancers","route":"/key-papers/paper-bergethon-ros1-rearrangements-lung-jco-2012/"}]}}